Blind Intubation Through The Self-Pressurised Disposable Air-Q Laryngeal Intubation Mask: An International Multicentre Trial

NCT ID: NCT01906060

Last Updated: 2016-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The disposable Air-Q self-inflating laryngeal intubation mask (Air-Q, Mercury Medical, Clearwater, FL, USA) is an extra-glottic airway device which enables blind intubation with a tracheal tube. This intubating laryngeal airway device (ILA) is already commercially available and worldwide certificated (CE 0482), but data about the success rates of blind intubation via this device in adult patients are lacking. Success rates of blind intubations with the non-self-inflating device range between 57 and 97%.

Although the self-inflating disposable Air-Q device is certified for blind intubation, the success rate and rate of adverse events associated with this procedure have not been published so far. In a study comparing adverse events of conventional intubation with blind intubation via a different supra-glottic airway device (ILMA) the rates of sore throat and cough were comparable in both groups and were reported in 10-17% of the patients. In a pilot study using the non-self-inflating Air-Q for blind intubation in 19 patients, 10% reported dysphagia and one patient had a bilateral lingual nerve injury which was self-limited. One study using the self-pressurised disposable Air-Q for ventilation of children showed broncho- or laryngospasm in 3% and mucosal damage such as blood stained ILA or sore throat were reported in 1%.

This data suggests that the rate of adverse events using the Air-Q supra-glottic device are comparable to other devices such as LMA.

* Trial with medical device

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elective Surgery Requiring Tracheal Intubation Using an Oral Tracheal Tube

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Air-Q Intubation Laryngeal Mask

Patients will be intubated using the Air-Q Intubation Laryngeal Mask and subsequently intubated with a commercially available endotracheal tube via the Intubation Laryngeal Mask.

Group Type EXPERIMENTAL

Air-Q Intubation Laryngeal Mask

Intervention Type DEVICE

Patients will be intubated using the Air-Q Laryngeal Mask.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Air-Q Intubation Laryngeal Mask

Patients will be intubated using the Air-Q Laryngeal Mask.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* elective surgery requiring tracheal intubation using an oral tracheal tube
* anticipated extubation in the operating room
* American Society of Anaesthesiologist Physical Status 1-3
* age = 18 years and = 85 years
* oral and written informed consent
* weight = 100kg (according to the product description)
* ability to understand the study information

Exclusion Criteria

* pharyngeal, laryngeal or tracheal pathology, including tracheostomy
* mouth opening \< 2.5 cm
* any form of airway infection such as upper-respiratory tract infection, pneumonia or suspected tuberculosis
* any disease that might impair the power of judgement (psychiatric disease, dementia)
* indicated rapid sequence induction which is a standard when high risk for regurgitation and/or aspiration is present
* the subject must not be involved in any other clinical trial during the course of this trial, nor within a period of 30 days prior to its beginning or 30 days after its completion
* pregnancy
* breast feeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Donat R. Spahn, Prof MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Zurich, Institute of Anaesthesiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University Lodz

Lodz, , Poland

Site Status

University Hospital Zurich, Institute of Anaesthesiology

Zurich, Canton of Zurich, Switzerland

Site Status

KantonsSpital Winterthur

Winterthur, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-0151

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.